
  
    
      
        Background_NNP
        The_DT thalassemias_NNS are_VBP a_DT group_NN of_IN inherited_VBN disorders_NNS of_IN
        hemoglobin_NN [_NN 1_CD ]_NN ,_, the_DT most_RBS severe_JJ form_NN of_IN which_WDT is_VBZ beta_NN
        thalassemia_NN major_JJ ._. Improvements_NNP in_IN the_DT management_NN of_IN
        patients_NNS with_IN thalassemia_NN major_JJ in_IN the_DT past_JJ four_CD decades_NNS
        have_VBP resulted_VBN in_IN "_'' one_CD of_IN the_DT most_RBS dramatic_JJ alterations_NNS in_IN
        morbidity_NN and_CC mortality_NN associated_VBN with_IN a_DT genetic_JJ disease_NN "_''
        [_NN 2_CD ]_NN ._. Regular_JJ red_JJ blood_NN cell_NN transfusions_NNS extend_VBP
        survival_NN ,_, eliminate_VB complications_NNS of_IN anemia_NN ,_, inhibit_VB bone_NN
        marrow_NN hyperactivity_NN ,_, and_CC support_VB normal_JJ growth_NN and_CC
        development_NN in_IN patients_NNS with_IN thalassemia_NN major_JJ [_NN 3_CD ]_NN ._.
        Unfortunately_RB ,_, regular_JJ transfusions_NNS also_RB lead_VBP to_TO the_DT
        accumulation_NN of_IN tissue_NN iron_NN ,_, loading_VBG the_DT body_NN 's_POS organs_NNS to_TO
        the_DT point_NN of_IN dysfunction_NN and_CC finally_RB death_NN in_IN the_DT second_JJ or_CC
        third_JJ decade_NN of_IN life_NN if_IN left_VBD untreated_JJ [_NN 4_CD ]_NN ._.
        To_TO alleviate_VB iron_NN loading_NN ,_, chelating_VBG agents_NNS such_JJ as_IN
        desferrioxamine_NN (_( Desferal_NNP ®_NN )_) and_CC ,_, most_RBS recently_RB ,_,
        deferiprone_NN (_( Ferriprox_NNP ®_NN )_) are_VBP available_JJ ._. As_IN a_DT complement_VB to_TO
        frequent_JJ blood_NN transfusions_NNS ,_, proper_JJ iron_NN chelation_NN therapy_NN
        further_JJ improves_VBZ the_DT quality_NN of_IN the_DT patient_NN 's_POS life_NN and_CC
        extends_VBZ survival_NN ,_, impeding_VBG iron_NN loading_NN complications_NNS ._.
        Successful_JJ management_NN of_IN thalassemia_NN major_JJ relies_VBZ upon_IN
        accurate_JJ assessment_NN of_IN body_NN iron_NN burden_NN ._. Several_JJ indirect_JJ
        assessment_NN methods_NNS are_VBP available_JJ ,_, among_IN which_WDT are_VBP
        measurement_NN of_IN serum_NN ferritin_NN levels_NNS ,_, urinary_JJ iron_NN
        excretion_NN ,_, and_CC hepatic_JJ iron_NN quantification_NN ._. While_IN no_DT one_CD
        method_NN is_VBZ superior_JJ for_IN all_DT clinical_JJ scenarios_NNS ,_, until_IN
        recently_RB measurement_NN of_IN hepatic_JJ iron_NN stores_NNS -_: through_IN liver_NN
        biopsy_NN or_CC magnetic_JJ susceptometry_NN -_: has_VBZ provided_VBN the_DT most_RBS
        quantitative_JJ ,_, specific_JJ and_CC sensitive_JJ method_NN for_IN determining_VBG
        the_DT body_NN iron_NN burden_NN in_IN patients_NNS with_IN thalassemia_NN major_JJ and_CC
        was_VBD considered_VBN the_DT reference_NN method_NN for_IN comparison_NN with_IN
        other_JJ techniques_NNS [_NN 2_CD 4_CD ]_NN ._. In_IN the_DT future_NN ,_, the_DT newer_JJR
        advanced_VBD magnetic-resonance_JJ techniques_NNS ,_, which_WDT allow_VBP for_IN the_DT
        assessment_NN of_IN both_DT liver_NN and_CC cardiac_JJ iron_NN ,_, might_MD provide_VB an_DT
        even_RB more_RBR accurate_JJ assessment_NN of_IN total_JJ body_NN iron_NN [_NN 5_CD ]_NN ._.
        Measurement_NNP of_IN the_DT magnitude_NN of_IN iron_NN loading_NN is_VBZ useful_JJ in_IN
        evaluating_VBG the_DT effectiveness_NN of_IN the_DT chelating_VBG agent_NN ,_,
        calibrating_VBG patient-specific_JJ treatment_NN ,_, and_CC ,_, in_IN clinical_JJ
        research_NN ,_, as_IN a_DT determinant_NN of_IN clinical_JJ outcome_NN ._.
        The_DT literature_NN on_IN desferrioxamine_NN and_CC deferiprone_NN lacks_VBZ
        consensus_NN on_IN their_PRP$ comparative_JJ effectiveness_NN and_CC even_RB on_IN
        the_DT methods_NNS for_IN its_PRP$ quantification_NN ._. The_DT current_JJ evidence_NN is_VBZ
        comprised_VBN of_IN many_JJ small_JJ non-comparative_JJ studies_NNS that_WDT
        evaluate_VBP the_DT efficacy_NN of_IN a_DT chelator_NN in_IN the_DT short-_NN or_CC ,_, more_RBR
        rarely_RB ,_, long-term_JJ ._. Moreover_RB ,_, a_DT significant_JJ impediment_NN to_TO
        comparing_VBG study_NN outcomes_NNS is_VBZ variation_NN in_IN the_DT method_NN
        employed_VBN to_TO measure_VB iron_NN burden_NN ._. Several_JJ systematic_JJ reviews_NNS
        of_IN the_DT literature_NN have_VBP been_VBN published_VBN [_NN 2_CD 6_CD 7_CD 8_CD ]_NN ._. None_NN of_IN
        them_PRP are_VBP quantitative_JJ comparisons_NNS of_IN the_DT efficacy_NN of_IN the_DT
        primary_JJ chelators_NNS ._. We_PRP undertook_VBD a_DT quantitative_JJ review_NN of_IN
        the_DT literature_NN to_TO estimate_VB the_DT effectiveness_NN of_IN
        desferrioxamine_NN and_CC deferiprone_NN in_IN decreasing_VBG hepatic_JJ iron_NN
        concentrations_NNS (_( HIC_NNP )_) in_IN thalassemia_NN major_JJ ._.
      
      
        Methods_NNP
        
          Search_NNP strategy_NN and_CC data_NNS extraction_NN
          All_DT studies_NNS of_IN desferrioxamine_NN and_CC deferiprone_NN usage_NN
          in_IN thalassemia_NN major_JJ patients_NNS -_: whether_IN randomized_JJ ,_,
          blinded_JJ ,_, comparative_JJ ,_, case_NN series_NN ,_, or_CC cross-over_JJ -_:
          irrespective_RB of_IN language_NN were_VBD considered_VBN eligible_JJ for_IN
          inclusion_NN in_IN the_DT analysis_NN ._. Although_IN preference_NN is_VBZ usually_RB
          given_VBN to_TO randomized_JJ controlled_VBN trials_NNS -_: as_IN they_PRP provide_VBP
          the_DT strongest_JJS ,_, least_RBS biased_VBN evidence_NN of_IN efficacy_NN -_: the_DT
          scanty_NN information_NN available_JJ for_IN thalassemia_NN forced_VBD us_PRP to_TO
          consider_VB all_DT study_NN types_NNS ._. Indeed_RB ,_, to_TO our_PRP$ knowledge_NN ,_, only_RB
          one_CD randomized_JJ controlled_VBN trial_NN comparing_VBG desferrioxamine_NN
          and_CC deferiprone_NN has_VBZ been_VBN conducted_VBN and_CC results_NNS for_IN that_DT
          study_NN are_VBP incomplete_JJ as_IN the_DT trial_NN was_VBD terminated_VBN
          prematurely_RB and_CC has_VBZ not_RB been_VBN reported_VBN in_IN full_JJ [_NN 9_CD 10_CD 11_CD ]_NN
          ._.
          The_DT National_NNP Library_NNP of_IN Medicine_NNP 's_POS computerized_JJ
          bibliographic_JJ database_NN (_( Medline_NNP 1966_CD to_TO December_NNP 1999_CD )_)
          was_VBD searched_VBD using_VBG a_DT combination_NN of_IN the_DT following_JJ
          keywords_NNS :_: thalassemia_NN ,_, serum_NN ferritin_NN ,_, urinary_JJ iron_NN
          excretion_NN ,_, hepatic_JJ iron_NN ,_, liver_NN ,_, chelation_NN therapy_NN ,_, iron_NN
          chelation_NN ,_, iron_NN chelating_VBG agents_NNS ,_, desferal_NN ,_,
          desferrioxamine_NN ,_, deferoxamine_NN ,_, L_NNP 1_CD oral_JJ chelate_NN ,_,
          deferiprone_NN and_CC 1_CD ,_, 2_CD -_: dimethyl-_NN 3_CD -_: hydroxypyrid-_NN 4_CD -_: one_CD ._. The_DT
          Medline_NNP search_NN was_VBD augmented_JJ by_IN manually_RB searching_VBG the_DT
          reference_NN lists_NNS of_IN retrieved_VBD studies_NNS and_CC reviews_NNS and_CC by_IN
          reviewing_VBG abstracts_NNS from_IN conference_NN proceedings_NNS ._. The_DT
          studies_NNS identified_VBN were_VBD carefully_RB evaluated_VBN for_IN
          eligibility_NN ;_: they_PRP were_VBD included_VBN if_IN they_PRP (_( i_NNP )_) enrolled_VBD
          subjects_NNS with_IN thalassemia_NN major_JJ -_: irrespective_RB of_IN age_NN at_IN
          diagnosis_NN ,_, treatment_NN initiation_NN or_CC study_NN start_NN nor_CC of_IN
          treatment_NN history_NN in_IN terms_NNS of_IN transfusion_NN regimen_NN or_CC iron_NN
          chelation_NN ;_: (_( ii_NN )_) followed_VBN patients_NNS treated_VBN with_IN either_DT
          desferrioxamine_NN administered_VBN subcutaneously_RB or_CC
          intravenously_RB or_CC oral_JJ deferiprone_NN ;_: and_CC (_( iii_NN )_) measured_VBN
          hepatic_JJ iron_NN concentrations_NNS to_TO evaluate_VB treatment_NN
          efficacy_NN ._. Studies_NNS aimed_VBD at_IN comparing_VBG the_DT relative_JJ
          performance_NN of_IN different_JJ measurement_NN techniques_NNS (_( e_SYM ._. g_SYM ._. ,_,
          liver_NN biopsy_NN versus_CC MRI_NNP )_) were_VBD excluded_VBN ._. Abstracts_NNP that_WDT
          provided_VBD sufficient_JJ information_NN on_IN the_DT endpoint_NN under_IN
          consideration_NN were_VBD retained_VBN for_IN the_DT analysis_NN ._.
          Duplications_NNP were_VBD identified_VBN and_CC only_RB the_DT original_JJ or_CC ,_, if_IN
          pertinent_JJ ,_, most_RBS extensive_JJ report_NN was_VBD included_VBN ._. No_DT
          exclusions_NNS were_VBD implemented_VBN on_IN the_DT basis_NN of_IN sample_NN size_NN ,_,
          study_NN quality_NN or_CC study_NN duration_NN ._.
          Details_NNS on_IN study_NN design_NN ,_, length_NN of_IN follow-up_JJ ,_, number_NN
          of_IN patients_NNS included_VBD ,_, patient_NN age_NN ,_, presence_NN of_IN iron_NN
          overload-related_JJ complications_NNS at_IN study_NN start_NN ,_, prior_RB and_CC
          current_JJ iron_NN chelation_NN (_( drug_NN ,_, route_NN ,_, dose_NN )_) ,_, use_NN of_IN
          concomitant_NN medication_NN and_CC outcome_NN measures_NNS were_VBD
          extracted_VBN independently_RB by_IN two_CD investigators_NNS using_VBG a_DT
          standardized_JJ electronic_JJ data_NNS collection_NN form_NN ._.
          Investigators_NNS were_VBD not_RB blinded_JJ to_TO journal_NN ,_, author_NN ,_,
          institution_NN or_CC treatment_NN ._. All_DT differences_NNS in_IN extracted_VBN
          data_NNS were_VBD resolved_VBN by_IN consensus_NN between_IN the_DT two_CD
          extractors_NNS prior_RB to_TO locking_VBG the_DT database_NN ._.
        
        
          Statistical_NNP analysis_NN
          The_DT main_JJ analyses_NNS were_VBD conducted_VBN using_VBG individual_JJ
          patient_NN level_NN data_NNS ,_, as_IN the_DT majority_NN of_IN studies_NNS reported_VBD
          this_DT level_NN of_IN detail_NN ._. For_IN the_DT purpose_NN of_IN these_DT analyses_NNS ,_,
          all_DT HIC_NNP had_VBD to_TO be_VB converted_VBN from_IN the_DT original_JJ value_NN to_TO a_DT
          common_JJ measurement_NN unit_NN ._. We_PRP opted_VBD for_IN mg_NN /_NN g_SYM dry_JJ liver_NN
          weight_NN ._. For_IN each_DT patient_NN ,_, we_PRP calculated_VBD the_DT absolute_JJ
          change_NN in_IN HIC_NNP over_IN the_DT study_NN period_NN and_CC a_DT "_'' responder_NN "_'' was_VBD
          defined_VBN as_IN showing_VBG any_DT improvement_NN ._. The_DT relative_JJ change_NN
          was_VBD calculated_VBN as_IN the_DT absolute_JJ change_NN divided_VBN by_IN the_DT
          baseline_JJ HIC_NNP ._.
          The_DT mean_NN HIC_NNP at_IN study_NN end_NN was_VBD calculated_VBN for_IN each_DT
          treatment_NN ._. As_IN initial_JJ hepatic_JJ iron_NN load_NN was_VBD greater_JJR ,_, on_IN
          average_JJ ,_, in_IN patients_NNS receiving_VBG desferrioxamine_NN ,_, the_DT
          comparison_NN of_IN the_DT means_NNS needed_VBN to_TO take_VB this_DT into_IN account_NN ._.
          This_DT was_VBD done_VBN by_IN carrying_VBG out_RP an_DT ANCOVA_NNP ,_, controlling_VBG for_IN
          HIC_NNP at_IN baseline_NN ._. A_DT second_JJ analysis_NN was_VBD conducted_VBN to_TO
          evaluate_VB the_DT proportion_NN of_IN responders_NNS ,_, and_CC the_DT χ_NN 2_CD -_: test_NN
          was_VBD used_VBN to_TO test_VB for_IN differences_NNS in_IN these_DT proportions_NNS ._.
          The_DT odds_NNS ratio_NN of_IN improvement_NN and_CC its_PRP$ 95_CD %_NN confidence_NN
          interval_NN were_VBD also_RB calculated_VBN ._. Next_JJ ,_, for_IN the_DT subset_NN of_IN
          patients_NNS who_WP showed_VBD improvement_NN over_IN time_NN ,_, the_DT mean_JJ
          relative_JJ change_NN in_IN HIC_NNP was_VBD compared_VBN ._.
          Although_IN no_DT fixed_VBN dose_NN of_IN either_DT treatment_NN is_VBZ optimal_NN
          for_IN all_DT patients_NNS [_NN 12_CD ]_NN ,_, an_DT attempt_NN was_VBD made_VBN to_TO
          differentiate_VB what_WP would_MD generally_RB be_VB considered_VBN a_DT
          suboptimal_NN dose_NN for_IN each_DT treatment_NN in_IN line_NN with_IN current_JJ
          treatment_NN recommendations_NNS ._. For_IN desferrioxamine_NN ,_, this_DT was_VBD
          defined_VBN as_IN less_JJR than_IN 40_CD mg_NN /_NN kg_NN /_NN day_NN ._. For_IN deferiprone_NN ,_, the_DT
          corresponding_JJ threshold_NN was_VBD 75_CD mg_NN /_NN kg_NN /_NN day_NN ._. It_PRP should_MD be_VB
          noted_VBN that_DT information_NN on_IN the_DT specific_JJ dose_NN used_VBN by_IN
          individual_JJ patients_NNS was_VBD not_RB provided_VBN for_IN the_DT majority_NN of_IN
          the_DT studies_NNS ,_, where_WRB the_DT dose_NN varied_VBD over_IN a_DT certain_JJ range_NN ._.
          Rather_RB than_IN ignore_VB the_DT potential_JJ impact_NN of_IN dose_NN on_IN the_DT
          outcome_NN measure_NN ,_, we_PRP assigned_VBN the_DT mean_JJ dose_NN reported_VBD for_IN
          the_DT entire_JJ study_NN population_NN to_TO each_DT individual_NN within_IN a_DT
          particular_JJ study_NN ._. Analyses_NNS were_VBD carried_VBN out_IN by_IN dose_NN ._.
          Finally_RB ,_, additional_JJ analyses_NNS were_VBD conducted_VBN to_TO explore_VB
          the_DT impact_NN on_IN the_DT odds_NNS of_IN improvement_NN of_IN including_VBG the_DT
          few_JJ studies_NNS that_WDT provided_VBD summary_NN information_NN at_IN the_DT
          study_NN level_NN only_RB ._.
          We_PRP considered_VBD a_DT p-value_JJ less_JJR than_IN 0_CD ._. 05_CD to_TO be_VB
          significant_JJ for_IN all_DT statistical_JJ tests_NNS ._. No_DT correction_NN for_IN
          multiple_JJ comparisons_NNS was_VBD made_VBN ._. Analyses_NNS were_VBD carried_VBN out_IN
          with_IN SAS_NNP version_NN 6_CD ._. 12_CD for_IN Windows_NNP ._.
        
        
          Role_NNP of_IN funding_NN source_NN
          The_DT funding_NN source_NN had_VBD no_DT role_NN in_IN the_DT collection_NN ,_,
          analysis_NN ,_, or_CC interpretation_NN of_IN the_DT data_NNS ._.
        
      
      
        Results_NNS
        
          Hepatic_NNP iron_NN concentrations_NNS at_IN endpoint_NN
          The_DT mean_NN HIC_NNP at_IN endpoint_NN ,_, considering_VBG all_DT patients_NNS ,_,
          was_VBD 14_CD ._. 4_LS mg_NN /_NN g_SYM ._. Based_VBN on_IN clinical_JJ experience_NN with_IN
          hereditary_JJ hemochromatosis_NNS ,_, the_DT optimal_NN range_NN for_IN HIC_NNP in_IN
          patients_NNS with_IN thalassemia_NN major_NN is_VBZ considered_VBN to_TO be_VB
          between_IN 3_CD ._. 2_CD and_CC 7_CD ._. 0_CD mg_NN /_NN g_SYM dry_JJ weight_NN ,_, above_IN which_WDT patients_NNS
          run_VBP an_DT increased_VBN risk_NN of_IN complications_NNS ,_, including_VBG hepatic_JJ
          fibrosis_NNS ,_, diabetes_NN mellitus_JJ ,_, and_CC -_: at_IN concentrations_NNS
          above_IN 15_CD mg_NN /_NN g_SYM -_: of_IN cardiac_JJ disease_NN and_CC early_JJ death_NN [_NN 2_CD ]_NN
          ._. At_IN the_DT end_NN of_IN the_DT respective_JJ observation_NN periods_NNS ,_, 67_CD ._. 3_LS %_NN
          of_IN all_DT treated_VBN patients_NNS still_RB had_VBD an_DT HIC_NNP over_IN 7_CD ._. 0_CD mg_NN /_NN g_SYM ,_,
          compared_VBN to_TO 85_CD ._. 7_CD %_NN of_IN patients_NNS at_IN the_DT start_NN ._.
          Figure_NN 1_CD clearly_RB illustrates_VBZ the_DT anticipated_VBN
          correlation_NN between_IN initial_JJ and_CC final_JJ HIC_NNP and_CC ,_, therefore_RB ,_,
          the_DT importance_NN of_IN controlling_VBG for_IN initial_JJ hepatic_JJ iron_NN
          load_NN in_IN comparative_JJ analyses_NNS ._. Hepatic_NNP iron_NN load_NN at_IN study_NN
          end_NN -_: controlling_VBG for_IN initial_JJ hepatic_JJ iron_NN load_NN -_: was_VBD
          found_VBN to_TO be_VB significantly_RB lower_JJR in_IN
          desferrioxamine-treated_JJ patients_NNS (_( adjusted_VBN mean_VB :_: 6_CD ._. 4_CD
          mg_NN /_NN g_SYM )_) ,_, compared_VBN to_TO patients_NNS treated_VBN with_IN either_DT optimal_NN
          dose_NN (_( 15_CD ._. 3_LS mg_NN /_NN g_SYM )_) or_CC low_JJ dose_NN (_( 24_CD ._. 3_LS mg_NN /_NN g_SYM )_) deferiprone_NN
          (_( overall_JJ p_NN <_NN 0_CD ._. 0001_CD ;_: p_NN =_SYM 0_CD ._. 06_CD and_CC p_NN =_SYM 0_CD ._. 0002_CD for_IN
          pairwise_NN comparisons_NNS of_IN desferrioxamine_NN vs_NNS optimal_NN and_CC
          low_JJ dose_NN deferiprone_NN ,_, respectively_RB )_) ._.
        
        
          Changes_NNS in_IN hepatic_JJ iron_NN concentration_NN over_IN
          time_NN
          Overall_RB ,_, 65_CD of_IN the_DT 98_CD patients_NNS showed_VBD an_DT improvement_NN
          in_IN HIC_NNP ._. Patients_NNS treated_VBD with_IN desferrioxamine_NN were_VBD more_RBR
          likely_JJ to_TO improve_VB than_IN patients_NNS treated_VBN with_IN optimal_NN dose_NN
          (_( OR_NNP :_: 19_CD ._. 0_CD ;_: 95_CD %_NN CI_NNP :_: 2_CD ._. 4_CD -_: 151_CD ._. 4_LS )_) or_CC low_JJ dose_NN (_( OR_NNP :_: 53_CD ._. 9_CD ;_:
          95_CD %_NN CI_NNP :_: 6_CD ._. 0_CD -_: 483_CD ._. 7_CD )_) deferiprone_NN within_IN the_DT study_NN
          observation_NN periods_NNS (_( Figure_NN 2_LS )_) ._. Controlling_NNP for_IN hepatic_JJ
          iron_NN load_NN at_IN baseline_NN did_VBD not_RB affect_VB these_DT results_NNS ._.
          Among_IN the_DT 65_CD patients_NNS who_WP improved_VBD over_IN time_NN ,_, the_DT
          hepatic_JJ iron_NN load_NN decreased_VBD significantly_RB more_JJR in_IN
          desferrioxamine-treated_JJ patients_NNS :_: by_IN 60_CD ._. 2_LS %_NN (_( an_DT average_NN of_IN
          15_CD ._. 8_CD mg_NN /_NN g_SYM )_) ,_, compared_VBN with_IN 45_CD ._. 3_LS %_NN (_( 12_CD ._. 4_LS mg_NN /_NN g_SYM )_) in_IN
          deferiprone_NN optimal_NN dose_NN and_CC 33_CD ._. 5_LS %_NN (_( 10_CD ._. 7_CD mg_NN /_NN g_SYM )_) in_IN
          deferiprone_NN low_JJ dose_NN (_( overall_JJ p_NN <_NN 0_CD ._. 01_CD ;_: findings_NNS
          confirmed_VBD in_IN pairwise_NN comparisons_NNS )_) ._.
        
        
          Inclusion_NNP of_IN additional_JJ studies_NNS
          We_PRP explored_JJ the_DT impact_NN of_IN the_DT three_CD studies_NNS that_WDT did_VBD
          not_RB provide_VB individual_JJ patient_NN data_NNS by_IN including_VBG them_PRP in_IN
          additional_JJ analyses_NNS ._. To_TO allow_VB for_IN this_DT analysis_NN ,_,
          "_'' improvement_NN "_'' had_VBD to_TO be_VB defined_VBN for_IN each_DT study_NN ,_, as_IN
          results_NNS were_VBD reported_VBN in_IN slightly_RB different_JJ ways_NNS
          depending_VBG on_IN the_DT study_NN ._. Patients_NNS in_IN the_DT study_NN conducted_VBN
          by_IN Diav-_NNP Citrin_NNP [_NN 22_CD ]_NN were_VBD all_DT treated_VBN with_IN deferiprone_NN
          and_CC we_PRP defined_VBD improvement_NN as_IN HIC_NNP that_WDT were_VBD reduced_VBN or_CC
          maintained_VBN at_IN less_JJR than_IN 7_CD mg_NN /_NN g_SYM of_IN dry_JJ weight_NN liver_NN
          tissue_NN ._. A_DT threshold_NN of_IN 15_CD mg_NN /_NN g_SYM tissue_NN iron_NN had_VBD to_TO be_VB used_VBN
          instead_RB for_IN the_DT comparative_JJ study_NN conducted_VBN by_IN Olivieri_NNP
          and_CC colleagues_NNS due_JJ to_TO how_WRB these_DT researchers_NNS summarize_VB the_DT
          results_NNS [_NN 11_CD ]_NN ._. For_IN the_DT study_NN by_IN Longo_NNP and_CC colleagues_NNS [_NN
          18_CD ]_NN ,_, patients_NNS receiving_VBG deferiprone_NN who_WP were_VBD in_IN a_DT
          negative_JJ or_CC stable_JJ iron_NN balance_NN at_IN the_DT end_NN of_IN the_DT
          observation_NN period_NN were_VBD considered_VBN to_TO have_VB improved_VBN ._.
          The_DT odds_NNS ratios_NNS presented_VBN in_IN Figure_NN 2_CD demonstrate_VB that_IN
          the_DT findings_NNS remain_VBP largely_RB in_IN favor_NN of_IN desferrioxamine_NN
          in_IN all_DT scenarios_NNS examined_VBD ;_: that_DT is_VBZ ,_, the_DT 95_CD %_NN CI_NNP do_VBP not_RB
          include_VB 1_CD ._.
        
      
      
        Discussion_NNP
        Based_VBN on_IN analyses_NNS of_IN individual_JJ patient_NN data_NNS from_IN eight_CD
        studies_NNS reporting_VBG on_IN changes_NNS in_IN HIC_NNP over_IN time_NN ,_,
        desferrioxamine_NN seems_VBZ to_TO be_VB more_RBR effective_JJ than_IN deferiprone_NN
        in_IN lowering_VBG hepatic_JJ iron_NN in_IN patients_NNS with_IN thalassemia_NN
        major_JJ ._. Indeed_RB ,_, the_DT analyses_NNS indicate_VBP that_DT desferrioxamine_NN
        not_RB only_RB increases_VBZ the_DT likelihood_NN of_IN lowering_VBG hepatic_JJ iron_NN
        load_NN ,_, but_CC also_RB tends_VBZ to_TO induce_VB larger_JJR reductions_NNS in_IN hepatic_JJ
        iron_NN among_IN responders_NNS ,_, even_RB after_IN controlling_VBG for_IN the_DT
        imbalance_NN in_IN HIC_NNP at_IN study_NN initiation_NN ._. These_DT results_NNS remain_VBP
        when_WRB including_VBG data_NNS from_IN three_CD additional_JJ studies_NNS that_WDT
        provided_VBD summary_NN information_NN only_RB ._.
        There_EX are_VBP several_JJ important_JJ qualifications_NNS to_TO these_DT
        results_NNS ._. The_DT doses_NNS of_IN deferiprone_NN -_: even_RB in_IN the_DT optimal_NN
        dose_NN group_NN -_: are_VBP relatively_RB low_JJ ,_, compared_VBN to_TO the_DT
        desferrioxamine_NN doses_NNS ,_, which_WDT in_IN most_JJS studies_NNS are_VBP well_RB above_IN
        the_DT recommended_VBN 40_CD mg_NN /_NN kg_NN /_NN day_NN ._. This_DT is_VBZ important_JJ in_IN light_NN of_IN
        the_DT strong_JJ connection_NN between_IN the_DT dose_NN of_IN the_DT iron_NN chelator_NN
        and_CC the_DT amount_NN of_IN iron_NN excreted_JJ ._. On_IN the_DT other_JJ hand_NN ,_, the_DT
        results_NNS from_IN the_DT only_RB randomized_JJ trial_NN suggest_VBP that_IN even_RB at_IN
        relatively_RB low_JJ doses_NNS ,_, desferrioxamine_NN outperforms_VBZ
        deferiprone_NN [_NN 11_CD ]_NN ._. Moreover_RB ,_, the_DT toxic_JJ :_: therapeutic_JJ ratio_NN
        of_IN deferiprone_NN is_VBZ reportedly_RB low_JJ ;_: doses_NNS of_IN 100_CD mg_NN /_NN kg_NN /_NN day_NN
        have_VBP resulted_VBN in_IN bone_NN marrow_NN toxicity_NN in_IN animals_NNS and_CC
        humans_NNS ._. Second_JJ ,_, liver_NN iron_NN concentration_NN is_VBZ only_RB one_CD of_IN the_DT
        outcome_NN parameters_NNS considered_VBN in_IN the_DT studies_NNS included_VBN in_IN
        our_PRP$ analyses_NNS and_CC in_IN several_JJ cases_NNS only_RB available_JJ for_IN a_DT
        small_JJ subset_NN of_IN the_DT entire_JJ study_NN population_NN [_NN 13_CD 14_CD 15_CD 16_CD
        21_CD ]_NN ._. As_IN it_PRP is_VBZ impossible_JJ to_TO determine_VB how_WRB or_CC why_WRB these_DT
        particular_JJ patients_NNS were_VBD selected_VBN for_IN repeated_VBN liver_NN
        biopsy_NN ,_, the_DT magnitude_NN and_CC direction_NN of_IN the_DT potential_JJ bias_NN
        this_DT may_MD have_VB caused_VBN cannot_NN be_VB ascertained_JJ ._. Finally_RB ,_, as_IN
        several_JJ of_IN the_DT patients_NNS included_VBN in_IN the_DT deferiprone_NN studies_NNS
        had_VBD previously_RB failed_VBN desferrioxamine_NN treatment_NN ,_, due_JJ to_TO
        non-compliance_JJ or_CC other_JJ reasons_NNS ,_, it_PRP could_MD be_VB postulated_JJ
        that_IN they_PRP are_VBP more_RBR likely_JJ to_TO do_VB badly_RB on_IN deferiprone_NN as_RB
        well_RB ._. Despite_IN the_DT fact_NN that_DT compliance_NN is_VBZ improved_VBN on_IN
        deferiprone_NN ,_, this_DT highlights_VBZ the_DT dangers_NNS of_IN assuming_VBG that_IN
        this_DT drug_NN ,_, with_IN potential_JJ toxicity_NN greater_JJR than_IN that_DT of_IN
        desferrioxamine_NN ,_, should_MD be_VB implemented_VBN in_IN patients_NNS
        struggling_VBG with_IN desferrioxamine_NN ,_, as_IN proposed_VBN by_IN some_DT
        clinicians_NNS ._.
        Comparison_NNP with_IN specific_JJ findings_NNS in_IN the_DT literature_NN is_VBZ
        difficult_JJ because_IN of_IN the_DT vast_JJ differences_NNS in_IN study_NN
        objectives_NNS ,_, patient_NN populations_NNS studied_VBN ,_, parameters_NNS
        evaluated_VBN ,_, and_CC analytical_JJ approach_NN ._. Broadly_NNP speaking_VBG ,_,
        however_RB ,_, our_PRP$ findings_NNS are_VBP in_IN accord_NN with_IN other_JJ published_VBN
        data_NNS ._. Several_JJ systematic_JJ ,_, qualitative_JJ reviews_NNS [_NN 2_CD 8_CD 23_CD 24_CD ]_NN
        highlight_NN the_DT clinical_JJ benefits_NNS of_IN desferrioxamine_NN
        treatment_NN and_CC ,_, with_IN respect_NN to_TO iron_VB loading_NN ,_, acknowledge_VBP
        its_PRP$ ability_NN to_TO maintain_VB harmless_JJ hepatic_JJ iron_NN levels_NNS in_IN
        properly_RB chelated_JJ patients_NNS ._. The_DT most_RBS recent_JJ of_IN these_DT
        reviews_NNS also_RB corroborate_VBP our_PRP$ finding_VBG that_IN
        deferiprone-treated_JJ patients_NNS do_VBP not_RB experience_VB the_DT same_JJ
        degree_NN of_IN improvement_NN in_IN hepatic_JJ iron_NN levels_NNS as_IN
        desferrioxamine-treated_JJ patients_NNS [_NN 2_CD 6_CD ]_NN and_CC some_DT project_NN
        further_JJ doubt_NN on_IN the_DT long-term_JJ implications_NNS of_IN deferiprone_NN
        treatment_NN [_NN 8_CD ]_NN ._.
        Measurement_NNP of_IN HIC_NNP has_VBZ been_VBN established_VBN in_IN the_DT field_NN as_IN
        the_DT reference_NN method_NN for_IN assessing_VBG total_JJ body_NN iron_NN burden_NN
        in_IN thalassemia_NN major_JJ ,_, and_CC therefore_RB preferred_VBN for_IN research_NN
        purposes_NNS ._. Nevertheless_RB ,_, the_DT methods_NNS of_IN measurement_NN (_( namely_RB
        liver_NN biopsy_NN and_CC superconducting_VBG quantum_NN interface_NN device_NN
        or_CC SQUID_NNP )_) are_VBP often_RB infeasible_JJ in_IN everyday_JJ practice_NN ._. Liver_NNP
        biopsies_NNS are_VBP neither_DT a_DT convenient_JJ [_NN 23_CD ]_NN nor_CC
        patient-preferred_JJ [_NN 2_CD 19_CD 25_CD ]_NN means_NNS of_IN monitoring_VBG efficacy_NN
        in_IN iron_NN chelation_NN therapy_NN ._. Even_RB less_RBR viable_JJ an_DT alternative_NN
        is_VBZ the_DT new_JJ ,_, noninvasive_JJ SQUID_NNP ,_, which_WDT is_VBZ both_DT prohibitively_RB
        expensive_JJ and_CC restricted_VBN to_TO only_RB three_CD especially-equipped_JJ
        sites_NNS :_: one_CD in_IN Germany_NNP ,_, one_CD in_IN Italy_NNP and_CC one_CD in_IN the_DT United_NNP
        States_NNPS [_NN 2_CD 8_CD ]_NN ._. Such_JJ constraints_NNS lie_VBP at_IN the_DT root_NN of_IN the_DT
        limited_JJ number_NN of_IN published_VBN studies_NNS that_WDT use_NN HIC_NNP as_IN the_DT
        efficacy_NN criterion_NN ,_, despite_IN its_PRP$ importance_NN to_TO clinical_JJ
        investigation_NN ._. It_PRP should_MD also_RB be_VB noted_VBN that_IN the_DT newer_JJR
        advanced_VBD magnetic-resonance_JJ techniques_NNS might_MD provide_VB a_DT more_RBR
        accurate_JJ assessment_NN of_IN total_JJ body_NN iron_NN than_IN liver_NN biopsy_NN or_CC
        SQUID_NNP because_IN iron_NN pools_NNS in_IN the_DT heart_NN and_CC liver_NN may_MD be_VB
        separate_JJ and_CC this_DT newer_JJR technique_NN allows_VBZ for_IN the_DT
        simultaneous_JJ assessment_NN of_IN both_DT hepatic_JJ and_CC myocardial_NN iron_NN
        concentrations_NNS [_NN 5_CD ]_NN ._.
        The_DT diversity_NN in_IN study_NN design_NN and_CC execution_NN as_RB well_RB as_IN
        the_DT reporting_NN of_IN the_DT results_NNS posed_VBD many_JJ challenges_NNS for_IN this_DT
        analysis_NN ._. The_DT literature_NN is_VBZ dominated_VBN by_IN observational_NN
        studies_NNS and_CC nonrandomized_JJ clinical_JJ trials_NNS performed_VBN on_IN
        small_JJ selected_VBN patient_NN cohorts_NNS ,_, thereby_RB making_VBG a_DT
        traditional_JJ meta-analysis_JJ impossible_JJ to_TO complete_VB ._. The_DT
        content_NN of_IN the_DT studies_NNS is_VBZ noteworthy_JJ as_IN well_RB ._. Many_JJ studies_NNS
        were_VBD carried_VBN out_IN without_IN treatment_NN protocols_NNS while_IN others_NNS
        reported_VBD results_NNS only_RB for_IN subgroups_NNS -_: usually_RB undefined_JJ ._.
        Still_RB other_JJ studies_NNS reported_VBD outcomes_NNS only_RB graphically_RB ,_,
        that_WDT is_VBZ ,_, without_IN providing_VBG the_DT precise_JJ values_NNS ._. A_DT further_JJ
        challenge_NN to_TO evaluating_VBG hepatic_JJ iron_NN as_IN reported_VBN in_IN the_DT
        published_VBN data_NN is_VBZ the_DT significant_JJ variation_NN in_IN measurement_NN
        units_NNS and_CC assessment_NN values_NNS (_( i_NNP ._. e_SYM ._. ,_, dry_JJ or_CC wet_JJ )_) ,_, as_IN Table_NNP
        2_CD illustrates_VBZ ._. For_IN example_NN ,_, the_DT wet-to-dry_JJ weight_NN liver_NN iron_NN
        conversions_NNS require_VBP an_DT assumption_NN of_IN liver_NN water_NN content_NN ,_,
        which_WDT ranges_VBZ from_IN 60_CD to_TO 75_CD percent_NN in_IN the_DT literature_NN [_NN 26_CD ]_NN
        ._. Due_JJ to_TO incomplete_JJ information_NN ,_, our_PRP$ analyses_NNS do_VBP not_RB take_VB
        into_IN account_NN some_DT potentially_RB important_JJ patient_NN
        characteristics_NNS ,_, such_JJ as_IN duration_NN of_IN treatment_NN
        administration_NN or_CC presence_NN of_IN iron-induced_JJ complications_NNS ,_,
        nor_CC the_DT patients_NNS '_POS transfusion_NN regimens_NNS ,_, all_DT of_IN which_WDT are_VBP
        used_VBN to_TO calibrate_NN appropriate_JJ dose_NN prescriptions_NNS and_CC may_MD
        influence_VB efficacy_NN outcomes_NNS [_NN 12_CD 21_CD 25_CD 27_CD ]_NN ._.
        Given_VBN the_DT methodological_JJ caveats_NNS and_CC the_DT heterogeneity_NN
        of_IN study_NN characteristics_NNS ,_, one_PRP could_MD legitimately_RB question_VB
        the_DT appropriateness_NN of_IN pooling_VBG the_DT results_NNS on_IN hepatic_JJ iron_NN
        concentration_NN across_IN studies_NNS ._. Physicians_NNPS must_MD still_RB select_VB
        the_DT optimal_NN treatment_NN for_IN their_PRP$ patients_NNS ,_, however_RB ,_,
        regardless_RB of_IN the_DT quality_NN of_IN the_DT evidence_NN ._. In_IN the_DT absence_NN
        of_IN large_JJ randomized_JJ well-controlled_JJ trials_NNS ,_, it_PRP was_VBD felt_VBN
        that_IN this_DT analysis_NN ,_, despite_IN its_PRP$ limitations_NNS ,_, would_MD
        summarize_VB the_DT evidence_NN in_IN a_DT useful_JJ way_NN ._. To_TO avoid_VB any_DT
        misleading_JJ conclusions_NNS we_PRP have_VBP sought_VBN to_TO be_VB completely_RB
        transparent_JJ about_IN the_DT underlying_VBG assumptions_NNS and_CC caveats_NNS of_IN
        the_DT analysis_NN ._.
        To_TO many_JJ ,_, deferiprone_NN may_MD not_RB appear_VB as_IN a_DT first-line_JJ
        chelator_NN but_CC rather_RB as_IN an_DT alternative_NN to_TO desferrioxamine_NN
        should_MD the_DT latter_NN not_RB be_VB usable_JJ ._. From_IN that_DT point_NN of_IN view_NN ,_,
        comparative_JJ effectiveness_NN may_MD not_RB be_VB an_DT issue_NN ._. The_DT analysis_NN
        presented_VBN here_RB casts_VBZ doubt_NN ,_, however_RB ,_, even_RB on_IN this_DT premise_NN
        that_DT deferiprone_NN offers_VBZ a_DT useful_JJ alternative_NN to_TO
        desferrioxamine_NN in_IN patients_NNS who_WP have_VBP difficulties_NNS with_IN the_DT
        administration_NN of_IN a_DT parenteral_NN drug_NN ._.
        Since_IN this_DT review_NN was_VBD completed_VBN ,_, two_CD important_JJ new_JJ
        studies_NNS have_VBP become_VBN available_JJ ._. In_IN the_DT first_JJ study_NN ,_, 144_CD
        patients_NNS with_IN thalassemia_NN major_JJ and_CC relatively_RB low_JJ serum_NN
        ferritin_NN concentrations_NNS (_( 1_CD ,_, 500_CD -_: 3_CD ,_, 000_CD ng_NN /_NN mL_NN )_) were_VBD
        randomized_JJ to_TO either_CC deferiprone_NN (_( n_NN =_SYM 71_CD )_) or_CC
        desferrioxamine_NN (_( n_NN =_SYM 73_CD )_) and_CC followed_VBN for_IN one_CD year_NN [_NN 28_CD ]_NN ._.
        Although_IN ,_, the_DT primary_JJ efficacy_NN measure_NN was_VBD the_DT reduction_NN of_IN
        serum_NN ferritin_NN ,_, HIC_NNP was_VBD assessed_VBN in_IN a_DT small_JJ subgroup_NN of_IN
        patients_NNS willing_JJ to_TO undergo_VB repeat_NN liver_NN biopsy_NN :_: 21_CD in_IN the_DT
        deferiprone_NN and_CC 15_CD in_IN the_DT desferrioxamine_NN group_NN ._. No_DT
        significant_JJ difference_NN in_IN the_DT reduction_NN of_IN HIC_NNP or_CC the_DT
        presence_NN of_IN liver_NN fibrosis_NNS was_VBD detected_VBN in_IN this_DT subgroup_NN of_IN
        patients_NNS ,_, leading_VBG the_DT authors_NNS to_TO conclude_VB that_IN both_DT
        treatments_NNS have_VBP a_DT similar_JJ chelating_VBG effect_NN over_IN a_DT
        relatively_RB short_JJ time_NN period_NN ._. This_DT apparent_JJ comparability_NN
        in_IN reduction_NN of_IN HIC_NNP is_VBZ in_IN conflict_NN ,_, however_RB ,_, with_IN the_DT
        results_NNS of_IN another_DT recently_RB published_VBN study_NN ._. A_DT case-control_JJ
        study_NN in_IN 15_CD patients_NNS treated_VBN with_IN deferiprone_NN (_( cases_NNS )_) and_CC
        30_CD patients_NNS treated_VBN with_IN desferrioxamine_NN (_( controls_NNS )_) matched_VBN
        for_IN age_NN and_CC serum_NN ferritin_NN levels_NNS ,_, demonstrated_VBN that_DT
        deferiprone_NN appears_VBZ to_TO be_VB more_RBR effective_JJ than_IN
        desferrioxamine_NN in_IN removal_NN of_IN myocardial_NN iron_NN 
        despite_IN significantly_RB higher_JJR HIC_NNP in_IN
        the_DT deferiprone_NN group_NN [_NN 5_CD ]_NN ._. Although_IN a_DT larger_JJR prospective_JJ
        trial_NN is_VBZ needed_VBN to_TO confirm_VB the_DT results_NNS ,_, these_DT findings_NNS
        would_MD suggest_VB that_IN a_DT combination_NN of_IN both_DT drugs_NNS may_MD be_VB most_RBS
        beneficial_JJ in_IN order_NN to_TO reduce_VB both_DT hepatic_JJ and_CC myocardial_NN
        concentrations_NNS of_IN iron_NN ._.
      
      
        Conclusions_NNP
        It_PRP has_VBZ been_VBN said_VBN that_IN a_DT meta-analysis_JJ is_VBZ only_RB useful_JJ
        until_IN the_DT next_JJ good_JJ trial_NN comes_VBZ along_IN [_NN 29_CD ]_NN ._. In_IN the_DT case_NN
        of_IN iron_NN chelation_NN therapy_NN for_IN patients_NNS with_IN thalassemia_NN
        major_JJ ,_, the_DT addition_NN of_IN 
        any_DT good_JJ prospective_JJ randomized_JJ
        control_NN trial_NN documenting_VBG the_DT impact_NN of_IN treatment_NN on_IN body_NN
        iron_NN (_( hepatic_JJ and_CC /_NN or_CC myocardial_NN )_) would_MD contribute_VB
        measurably_RB to_TO the_DT evaluation_NN of_IN the_DT long-term_JJ implications_NNS
        of_IN treatment_NN with_IN deferiprone_NN ,_, compared_VBN to_TO desferrioxamine_NN ._.
        Until_IN such_JJ a_DT study_NN becomes_VBZ available_JJ ,_, we_PRP present_VB this_DT
        comprehensive_JJ and_CC quantitative_JJ review_NN of_IN the_DT evidence_NN to_TO
        aid_VB patients_NNS with_IN thalassemia_NN major_JJ and_CC their_PRP$ physicians_NNS in_IN
        clinical_JJ judgment_NN and_CC treatment_NN decisions_NNS ._.
      
      
        Competing_VBG Interests_NNP
        This_DT work_NN was_VBD supported_VBN in_IN part_NN by_IN a_DT grant_NN from_IN Novartis_NNP
        Pharma_NNP AG_NNP Basel_NNP ,_, but_CC was_VBD carried_VBN out_IN without_IN influence_NN from_IN
        its_PRP$ sponsor_NN ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        Author_NN 1_CD (_( JJC_NNP )_) conceived_VBD and_CC designed_VBD the_DT study_NN ,_,
        interpreted_VBN results_NNS and_CC contributed_VBD to_TO writing_VBG the_DT
        manuscript_NN ._. Author_NN 2_CD (_( KFH_NNP )_) contributed_VBD to_TO the_DT study_NN design_NN ,_,
        did_VBD the_DT literature_NN search_NN and_CC data_NNS abstraction_NN ,_, conducted_VBD
        the_DT analyses_NNS ,_, interpreted_VBN results_NNS and_CC wrote_VBD the_DT manuscript_NN ._.
        Author_NN 3_CD (_( TCG_NNP )_) did_VBD the_DT literature_NN search_NN and_CC data_NNS
        abstraction_NN ,_, and_CC contributed_VBD to_TO writing_VBG the_DT manuscript_NN ._.
      
    
  
